XML 23 R7.htm IDEA: XBRL DOCUMENT v3.21.2
REVENUE RECOGNITION Revenue Recognition (Notes)
 6 Months Ended
Jun. 30, 2021
Revenue Recognition [Abstract]  
Revenue from Contract with Customer [Text Block] REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2021202020212020
Net product sales$11,405 $9,817 $22,203 $20,358 
Alliance revenues159 163 301 268 
Other revenues139 149 272 284 
Total Revenues$11,703 $10,129 $22,776 $20,910 

Products are sold principally to wholesalers, distributors, specialty pharmacies, and to a lesser extent, directly to retailers, hospitals, clinics and government agencies. Customer orders are generally fulfilled within a few days of receipt resulting in minimal order backlog. Contractual performance obligations are usually limited to transfer of control of the product to the customer. The transfer occurs either upon shipment, upon receipt of the product after considering when the customer obtains legal title to the product, or upon infusion for cell therapies and when BMS obtains a right of payment. At these points, customers are able to direct the use of and obtain substantially all of the remaining benefits of the product.

The following table summarizes GTN adjustments:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2021202020212020
Gross product sales$16,782 $13,788 $32,341 $28,474 
GTN adjustments(a)
Charge-backs and cash discounts(1,720)(1,292)(3,306)(2,632)
Medicaid and Medicare rebates(2,139)(1,482)(3,857)(2,980)
Other rebates, returns, discounts and adjustments(1,518)(1,197)(2,975)(2,504)
Total GTN adjustments(5,377)(3,971)(10,138)(8,116)
Net product sales$11,405 $9,817 $22,203 $20,358 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $85 million and $302 million for the three and six months ended June 30, 2021, and $44 million and $116 million for the three and six months ended June 30, 2020, respectively.
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in Millions2021202020212020
Prioritized Brands
Revlimid$3,202 $2,884 $6,146 $5,799 
Eliquis2,792 2,163 5,678 4,804 
Opdivo1,910 1,653 3,630 3,419 
Orencia814 750 1,572 1,464 
Pomalyst/Imnovid854 745 1,627 1,458 
Sprycel541 511 1,011 1,032 
Yervoy510 369 966 765 
Abraxane296 308 610 608 
Empliciti86 97 171 194 
Reblozyl128 55 240 63 
Inrebic16 15 32 27 
Onureg12 — 27 — 
Zeposia28 1 46 1 
Breyanzi17 — 17 — 
Abecma24 — 24 — 
Established Brands
Vidaza45 126 99 284 
Baraclude109 121 222 243 
Other Brands319 331 658 749 
Total Revenues$11,703 $10,129 $22,776 $20,910 
United States$7,388 $6,487 $14,398 $13,253 
Europe2,689 2,136 5,242 4,703 
Rest of the World1,435 1,334 2,781 2,669 
Other(a)
191 172 355 285 
Total Revenues$11,703 $10,129 $22,776 $20,910 
(a)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $146 million and $430 million for the three and six months ended June 30, 2021 and $98 million and $228 million for the three and six months ended June 30, 2020, respectively, consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties for out-licensing arrangements. Contract assets were not material at June 30, 2021 and December 31, 2020.